Next-gen CAR-T cell therapy shows early promise in patients with refractory B-cell acute lymphoblastic leukemia

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy that is manufactured in 48 hours using the T-Charge platform, show a manageable…

Continue Reading

News Source: medicalxpress.com